Captopril-triggered linear IgA bullous dermatosis.
Friedman
I S
IS
George Washington University School of Medicine, Washington, DC, USA.
Rudikoff
D
D
Phelps
R G
RG
Sapadin
A N
AN
D001323:Autoantibodies / Q000276:immunology*; D001485:Basement Membrane / Q000276:immunology / Q000473:pathology; D002216:Captopril / Q000009:adverse effects*; D003622:Dapsone / Q000627:therapeutic use; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology
D001323:Autoantibodies; D007070:Immunoglobulin A; D003622:Dapsone; D002216:Captopril; D011241:Prednisone